272 related articles for article (PubMed ID: 32972815)
1. Cost-analysis of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with peritoneal malignancy: An Australian perspective with global application.
McBride KE; Steffens D; Solomon MJ; Koh C; Ansari N; Young CJ; Moran B
Eur J Surg Oncol; 2021 Apr; 47(4):828-833. PubMed ID: 32972815
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in a community setting: A cost-utility analysis of a hospital's initial experience and reflections on the health care system.
Naffouje SA; O'Donoghue C; Salti GI
J Surg Oncol; 2016 Apr; 113(5):544-7. PubMed ID: 26750613
[TBL] [Abstract][Full Text] [Related]
3. Cost analysis of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy and the risk factors for their increased cost in a public insurance health care system - Single centre study.
Klos D; Riško J; Kriváčková D; Loveček M; Skalický P; Neoral Č; Melichar B; Mohelníková-Duchoňová B; Lemstrová R
Eur J Surg Oncol; 2020 Apr; 46(4 Pt A):607-612. PubMed ID: 31982207
[TBL] [Abstract][Full Text] [Related]
4. Association between hospital finances, payer mix, and complications after hyperthermic intraperitoneal chemotherapy: deficiencies in the current healthcare reimbursement system and future implications.
Squires MH; Staley CA; Knechtle W; Winer JH; Russell MC; Perez S; Sweeney JF; Maithel SK; Staley CA
Ann Surg Oncol; 2015 May; 22(5):1739-45. PubMed ID: 25249258
[TBL] [Abstract][Full Text] [Related]
5. Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy vs. cytoreductive surgery alone for intrahepatic cholangiocarcinoma with peritoneal metastases: A retrospective cohort study.
Feng F; Gao Q; Wu Y; Liu C; Yu Y; Li B; Chu K; Yi B; Cheng Q; Jiang X
Eur J Surg Oncol; 2021 Sep; 47(9):2363-2368. PubMed ID: 34119376
[TBL] [Abstract][Full Text] [Related]
6. Cost-Effectiveness Analysis of Cytoreductive Surgery and HIPEC Compared With Systemic Chemotherapy in Isolated Peritoneal Carcinomatosis From Metastatic Colorectal Cancer.
Hamilton TD; MacNeill AJ; Lim H; Hunink MGM
Ann Surg Oncol; 2019 Apr; 26(4):1110-1117. PubMed ID: 30690682
[TBL] [Abstract][Full Text] [Related]
7. Re-do cytoreductive surgery for peritoneal surface malignancy: Is it worthwhile?
Narasimhan V; Cheung F; Waters P; Peacock O; Warrier S; Lynch C; Michael M; Ramsay R; Heriot A
Surgeon; 2020 Oct; 18(5):287-294. PubMed ID: 31848069
[TBL] [Abstract][Full Text] [Related]
8. Accelerating the learning curve in cytoreductive surgery and hyperthermic intraperitoneal chemotherapy using an external mentor model.
Ansari N; Brown KGM; McBride KE; Steffens D; Koh CE; Young CJ; Solomon MJ; Moran BJ
ANZ J Surg; 2019 Sep; 89(9):1097-1101. PubMed ID: 31280498
[TBL] [Abstract][Full Text] [Related]
9. Major influence of postoperative complications on costs of cytoreductive surgery and HIPEC in patients with colorectal peritoneal metastases.
Simkens GA; Rovers KP; van Oudheusden TR; Nienhuijs SW; Rutten HJ; de Hingh IH
Medicine (Baltimore); 2018 Mar; 97(10):e0042. PubMed ID: 29517660
[TBL] [Abstract][Full Text] [Related]
10. Short-term outcomes in older patients with peritoneal malignancy treated with cytoreductive surgery and HIPEC: Experience with 245 patients from a national centre.
Keyes AM; Kelly ME; McInerney N; Khan MF; Bolger JC; McCormack E; Grundy J; McCormack O; MacHale J; Conneely J; Brennan D; Cahill R; Shields C; Moran B; Mulsow J
Eur J Surg Oncol; 2021 Sep; 47(9):2358-2362. PubMed ID: 33895028
[TBL] [Abstract][Full Text] [Related]
11. Learning Curve of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy - an Analysis of Critical Perioperative and Surgical Outcomes among 155 Peritoneal Surface Malignancy Patients Treated at a Tertiary Care Cancer Centre.
Saikia J; Deo S; Ray M; Mishra A; Bansal B; Bhoriwal S; Bhatnagar S; Mishra S; Bharti SJ; Kumar V; Kumar M
Clin Oncol (R Coll Radiol); 2022 Jul; 34(7):e305-e311. PubMed ID: 35379523
[TBL] [Abstract][Full Text] [Related]
12. Impact of extent of disease on 1-year healthcare costs in patients who undergo cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastases: retrospective observational cohort study.
Kooijman BJL; Hentzen JEKR; van der Hilst CS; Been LB; van Ginkel RJ; Hemmer PHJ; Klaase JM; Kruijff S
BJS Open; 2020 Oct; 4(5):954-962. PubMed ID: 32652904
[TBL] [Abstract][Full Text] [Related]
13. Enterocutaneous fistula in patients with peritoneal malignancy following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: Incidence, management and outcomes.
Valle SJ; Alzahrani N; Alzahrani S; Traiki TB; Liauw W; Morris DL
Surg Oncol; 2016 Sep; 25(3):315-20. PubMed ID: 27566038
[TBL] [Abstract][Full Text] [Related]
14. Repeat cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent diffuse malignant peritoneal mesothelioma.
Huang Y; Alzahrani NA; Liauw W; Morris DL
Eur J Surg Oncol; 2015 Oct; 41(10):1373-8. PubMed ID: 26227745
[TBL] [Abstract][Full Text] [Related]
15. Cost Effectiveness of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Management of Colorectal Peritoneal Carcinomatosis.
Lee ZJ; Chia SL; Tan G; Soo KC; Teo CCM
Ann Surg Oncol; 2018 Aug; 25(8):2340-2346. PubMed ID: 29948417
[TBL] [Abstract][Full Text] [Related]
16. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastases: outcomes from a national centre in the current era.
Kelly ME; Murphy E; Keyes AM; Khan MF; Bolger JC; Grundy J; Conneely J; MacHale J; McCaffrey J; Cahill R; Moran B; Shields C; Mulsow J
Ir J Med Sci; 2021 Nov; 190(4):1373-1377. PubMed ID: 33420573
[TBL] [Abstract][Full Text] [Related]
17. Laparoscopic cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for perforated low-grade appendiceal mucinous neoplasms.
Abudeeb H; Selvasekar CR; O'Dwyer ST; Chakrabarty B; Malcolmson L; Renehan AG; Wilson MS; Aziz O
Surg Endosc; 2020 Dec; 34(12):5516-5521. PubMed ID: 31993814
[TBL] [Abstract][Full Text] [Related]
18. Repeated cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with recurrent peritoneal carcinomatosis.
Vassos N; Förtsch T; Aladashvili A; Hohenberger W; Croner RS
World J Surg Oncol; 2016 Feb; 14(1):42. PubMed ID: 26912149
[TBL] [Abstract][Full Text] [Related]
19. Surgical and oncological outcomes after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy at a nonacademic center: 25-year experience.
Nikiforchin A; Gushchin V; King MC; Baron E; Nieroda C; Sittig M; Sardi A
J Surg Oncol; 2021 Mar; 123(4):1030-1044. PubMed ID: 33524164
[TBL] [Abstract][Full Text] [Related]
20. Patients with colorectal peritoneal metastases and high peritoneal cancer index may benefit from cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Birgisson H; Enblad M; Artursson S; Ghanipour L; Cashin P; Graf W
Eur J Surg Oncol; 2020 Dec; 46(12):2283-2291. PubMed ID: 32873455
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
